CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer
Yu Yan(Johns Hopkins University), Vanessa F. Merino(University of Maryland, Baltimore), Edward Gabrielson(Johns Hopkins University), Tao Huang(Shandong University), Martin G. Pomper(Southwestern Medical Center), Gabi Lofland(Johns Hopkins University), Marzieh Mazinani(Johns Hopkins University), Ali Afsari(Howard University), Athira Narayan(Johns Hopkins University), Yasmine Kanaan, Harumi Saeki(Juntendo University), Saraswati Sukumar(Johns Hopkins University), Tammey Naab(Howard University Hospital), Leslie Cope(Bloomberg (United States))
Cited by 0
Related Papers
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k